111 Capital Has $1.40 Million Position in Amgen Inc. $AMGN

Key Points

• 111 Capital cut its Amgen stake by 45.8% in the second quarter, selling 3,259 shares and retaining 3,851 shares valued at approximately $1.40 million. Institutional investors and hedge funds collectively own 76.5% of Amgen.
• Amgen reported stronger-than-expected quarterly results, with EPS of $6.29 versus the $5.62 consensus estimate and revenue of $10.05 billion. Revenue increased 9.5% year over year, while the company issued fiscal 2026 EPS guidance of $22.30–$23.50.
• The company declared a quarterly dividend of $2.52 per share, equal to an annualized $10.08 payout and a 2.4% yield. Analysts’ consensus rating remains “Hold,” with an average price target of $372.39, below the reported share price of $415.21.

111 Capital lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 45.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,851 shares of the medical research company's stock after selling 3,259 shares during the quarter. 111 Capital's holdings in Amgen were worth $1,395,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after purchasing an additional 55 shares during the period. Tower View Wealth Management LLC increased its position in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its stake in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in Amgen during the 4th quarter worth approximately $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $415.21 on Monday. The company's 50 day moving average is $370.57 and its 200-day moving average is $358.99. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $421.79. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $224.48 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts predict that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen's payout ratio is presently 62.65%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AMGN. BMO Capital Markets raised their price objective on Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Morgan Stanley raised their price target on shares of Amgen from $333.00 to $351.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 5th. Bank of America lifted their price target on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research note on Wednesday, August 5th. Weiss Ratings raised Amgen from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, August 6th. Finally, Canaccord Genuity Group increased their price objective on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $372.39.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source